Jay L. Koyner

Jay L. Koyner

Auto-generated profile, based on publicly available information

Jay L. Koyner

Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2013 in Critical Care
Verified
Journal Article
Open access
PDF file
Kianoush KashaniKianoush Kashani
Kianoush Kashani
AAAli Al-Khafaji
Ali Al-Khafaji
TAThomas Ardiles
Thomas Ardiles
Antonio ArtigasAntonio Artigas
Antonio Artigas
SBSean M Bagshaw
Sean M Bagshaw
JKJohn A Kellum
John A Kellum
Introduction: Acute kidney injury (AKI) can evolve quickly and clinical measures of function often fail to detect AKI at a time when interventions are likely to provide benefit. Identifying early markers of kidney damage has been difficult due to the complex nature of human AKI, in which multiple etiologies exist. The objective of this study was to identify and validate novel biomarkers of AKI. Methods: We performed two multicenter observational studies in critically ill patients at risk for AKI - discovery and validation. The top two markers from discovery were validated in a second study (Sapphire) and compared to a number of previously described biomarkers. In the discovery phase, we enrolled 522 adults in three distinct cohorts including patients with sepsis, shock, major surgery, and trauma and examined over 300 markers. In the Sapphire validation study, we enrolled 744 adult subjects with critical illness and without evidence of AKI at enrollment; the final analysis cohort was a heterogeneous sample of 728 critically ill patients. The primary endpoint was moderate to severe AKI (KDIGO stage 2 to 3) within 12 hours of sample collection. Results: Moderate to severe AKI occurred in 14% of Sapphire subjects. The two top biomarkers from discovery were validated. Urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), both inducers of G1 cell cycle arrest, a key mechanism implicated in AKI, together demonstrated an AUC of 0.80 (0.76 and 0.79 alone). Urine [TIMP-2]·[IGFBP7] was significantly superior to all previously described markers of AKI (P 0.72. Furthermore, [TIMP-2]·[IGFBP7] significantly improved risk stratification when added to a nine-variable clinical model when analyzed using Cox proportional hazards model, generalized estimating equation, integrated discrimination improvement or net reclassification improvement. Finally, in sensitivity analyses [TIMP-2]·[IGFBP7] remained significant and superior to all other markers regardless of changes in reference creatinine method. Conclusions: Two novel markers for AKI have been identified and validated in independent multicenter cohorts. Both markers are superior to existing markers, provide additional information over clinical variables and add mechanistic insight into AKI. Trial registration: ClinicalTrials.gov number NCT01209169.

23 February 2023 in Nature Reviews Nephrology
Verified
Journal Article
Open access
PDF file
AZAlexander Zarbock
Alexander Zarbock
MNMitra K. Nadim
Mitra K. Nadim
PPPeter Pickkers
Peter Pickkers
HGHernando Gomez
Hernando Gomez
SBSamira Bell
Samira Bell
LFLui Forni
Lui Forni
Sepsis-associated acute kidney injury (SA-AKI) is common in critically ill patients and is strongly associated with adverse outcomes, including an increased risk of chronic kidney disease, cardiovascular events and death. The pathophysiology of SA-AKI remains elusive, although microcirculatory dysfunction, cellular metabolic reprogramming and dysregulated inflammatory responses have been implicated in preclinical studies. SA-AKI is best defined as the occurrence of AKI within 7 days of sepsis onset (diagnosed according to Kidney Disease Improving Global Outcome criteria and Sepsis 3 criteria, respectively). Improving outcomes in SA-AKI is challenging, as patients can present with either clinical or subclinical AKI. Early identification of patients at risk of AKI, or at risk of progressing to severe and/or persistent AKI, is crucial to the timely initiation of adequate supportive measures, including limiting further insults to the kidney. Accordingly, the discovery of biomarkers associated with AKI that can aid in early diagnosis is an area of intensive investigation. Additionally, high-quality evidence on best-practice care of patients with AKI, sepsis and SA-AKI has continued to accrue. Although specific therapeutic options are limited, several clinical trials have evaluated the use of care bundles and extracorporeal techniques as potential therapeutic approaches. Here we provide graded recommendations for managing SA-AKI and highlight priorities for future research.

9 January 2019 in BMJ
Verified
Journal Article
Closed access
PDF file
JPJason T Poston
Jason T Poston
JKJay L Koyner
Jay L Koyner
Sepsis is defined as organ dysfunction resulting from the host’s deleterious response to infection. One of the most common organs affected is the kidneys, resulting in sepsis associated acute kidney injury (SA-AKI) that contributes to the morbidity and mortality of sepsis. A growing body of knowledge has illuminated the clinical risk factors, pathobiology, response to treatment, and elements of renal recovery that have advanced our ability to prevent, detect, and treat SA-AKI. Despite these advances, SA-AKI remains an important concern and clinical burden, and further study is needed to reduce the acute and chronic consequences. This review summarizes the relevant evidence, with a focus on the risk factors, early recognition and diagnosis, treatment, and long term consequences of SA-AKI. In addition to literature pertaining to SA-AKI specifically, pertinent sepsis and acute kidney injury literature relevant to SA-AKI was included.

20 September 2013 in Critical Care
Verified
Journal Article
Open access
PDF file
LCLakhmir S Chawla
Lakhmir S Chawla
DDDanielle L Davison
Danielle L Davison
EBErmira Brasha-Mitchell
Ermira Brasha-Mitchell
JKJay L Koyner
Jay L Koyner
JAJohn M Arthur
John M Arthur
MSMichael G Seneff
Michael G Seneff
Introduction: In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. Methods: We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI. Results: We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%. Conclusions: The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted.

3 August 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
MCMatthew M. Churpek
Matthew M. Churpek
KCKyle A. Carey
Kyle A. Carey
DEDana P. Edelson
Dana P. Edelson
TSTripti Singh
Tripti Singh
BABrad C. Astor
Brad C. Astor
JKJay L. Koyner
Jay L. Koyner
Acute kidney injury (AKI) is a common clinical syndrome in hospitalized patients and is associated with increased morbidity, mortality, and cost of care.1-3 Consensus criteria define AKI by either an increase in serum creatinine (SCr) concentration or a decrease in urine output.4 Biomarkers that detect AKI prior to these changes have been investigated for several years. However, to date, there has been limited large-scale validation and implementation of these tools. Detection of AKI prior to the changes in SCr concentration may provide a crucial window of opportunity to prevent further injury and allow clinicians to intervene in the hopes of improving patient outcomes.

15 September 2016 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
JKJay L. Koyner
Jay L. Koyner
RARicha Adhikari
Richa Adhikari
DEDana P. Edelson
Dana P. Edelson
MCMatthew M. Churpek
Matthew M. Churpek
Background and objectives Identification of patients at risk for AKI on the general wards before increases in serum creatinine would enable preemptive evaluation and intervention to minimize risk and AKI severity. We developed an AKI risk prediction algorithm using electronic health record data on ward patients (Electronic Signal to Prevent AKI). Design, setting, participants, & measurements All hospitalized ward patients from November of 2008 to January of 2013 who had serum creatinine measured in five hospitals were included. Patients with an initial ward serum creatinine >3.0 mg/dl or who developed AKI before ward admission were excluded. Using a discrete time survival model, demographics, vital signs, and routine laboratory data were used to predict the development of serum creatinine–based Kidney Disease Improving Global Outcomes AKI. The final model, which contained all variables, was derived in 60% of the cohort and prospectively validated in the remaining 40%. Areas under the receiver operating characteristic curves were calculated for the prediction of AKI within 24 hours for each unique observation for all patients across their inpatient admission. We performed time to AKI analyses for specific predicted probability cutoffs from the developed score. Results Among 202,961 patients, 17,541 (8.6%) developed AKI, with 1242 (0.6%) progressing to stage 3. The areas under the receiver operating characteristic curve of the final model in the validation cohort were 0.74 (95% confidence interval, 0.74 to 0.74) for stage 1 and 0.83 (95% confidence interval, 0.83 to 0.84) for stage 3. Patients who reached a cutoff of ≥0.010 did so a median of 42 (interquartile range, 14–107) hours before developing stage 1 AKI. This same cutoff provided sensitivity and specificity of 82% and 65%, respectively, for stage 3 and was reached a median of 35 (interquartile range, 14–97) hours before AKI. Conclusions Readily available electronic health record data can be used to improve AKI risk stratification with good to excellent accuracy. Real time use of Electronic Signal to Prevent AKI would allow early interventions before changes in serum creatinine and may improve costs and outcomes.